Edition:
United Kingdom

UDG Healthcare PLC (UDG.L)

UDG.L on London Stock Exchange

823.50GBp
23 Jan 2018
Change (% chg)

26.00 (+3.26%)
Prev Close
797.50
Open
799.00
Day's High
826.50
Day's Low
798.00
Volume
1,226,895
Avg. Vol
738,706
52-wk High
963.00
52-wk Low
632.50

Latest Key Developments (Source: Significant Developments)

Udg Healthcare Names Nigel Clerkin As CFO
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Udg Healthcare Plc ::CFO APPOINTMENT.‍CFO APPOINTMENT​.‍ANNOUNCE APPOINTMENT OF NIGEL CLERKIN AS CHIEF FINANCIAL OFFICER OF COMPANY​.‍NIGEL WILL START WITH COMPANY ON 1 MAY 2018 AND WILL REPLACE ALAN RALPH FROM THAT DATE​.‍ALAN WILL SUPPORT TRANSITION UNTIL HIS PREVIOUSLY ANNOUNCED RETIREMENT IN NOVEMBER 2018​.  Full Article

UDG Healthcare reports ‍FY net revenue growth of 12 pct to $1,028.5 mln​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - UDG Healthcare Plc ::SAYS ‍FY NET REVENUE GROWTH OF 12% (16% ON A CONSTANT CURRENCY BASIS) TO $1,028.5 MILLION.​.‍ADJUSTED DILUTED EARNINGS PER SHARE FROM CONTINUING OPERATIONS INCREASED BY 17%​.‍NET REVENUE GROWTH OF 12% (16% ON A CONSTANT CURRENCY BASIS) TO $1,028.5 MILLION​.SAYS ‍HAS NOW REDEPLOYED OVER TWO THIRDS OF NET PROCEEDS FROM 2016 SALE OF UNITED DRUG SUPPLY CHAIN BUSINESS TO MCKESSON​.PROPOSED 7.5% INCREASE IN FINAL DIVIDEND TO $9.72C PER SHARE, YIELDING A FULL YEAR DIVIDEND INCREASE OF 7% TO $13.3C PER SHARE​.‍UDG HEALTHCARE CHIEF FINANCIAL OFFICER, ALAN RALPH, HAS INFORMED BOARD THAT HE INTENDS TO RETIRE FROM HIS ROLE BY END OF 2018​.‍GROUP EXPECTS ORGANIC GROWTH TO ACCELERATE DURING SECOND HALF OF YEAR​.FY ‍ADJUSTED OPERATING PROFIT GROWTH OF 12% (17% ON A CONSTANT CURRENCY BASIS) TO $129.3 MILLION​.  Full Article

UDG Healthcare raises FY guidance for constant currency diluted EPS by 2 pct
Tuesday, 23 May 2017 

May 23 (Reuters) - Udg Healthcare Plc :Interim dividend of 3.58 cents per share .H1 pretax profit 52.9 million usd.HY IFRS revenue from continuing operations $578.9 million, up 8 percent.Increasing its guidance for constant currency diluted EPS for year to 30 Sep 2017 by 2% to a range of between 15% and 18% ahead of last year.While constant currency adjusted diluted EPS growth was 29% in H1 2017, does not expect this growth rate to be representative of full year outcome.Group is well positioned to deliver continued growth both organically and through strategic acquisitions.Group expects to continue its 30+ year history of dividend growth in fy17.Board has declared an interim dividend of 3.58c per share, a 5% increase on 2016 interim dividend.  Full Article

UDG Healthcare says Q3 revenue ahead of same period last year
Thursday, 4 Aug 2016 

UDG Healthcare Plc : Trading performance for quarter to 30 June 2016 has been good with group revenues and adjusted operating profits ahead of same period last year . Board has decided that from start of its next FY, 1 October 2016, group will present its financial results in us dollars .Reiterates FY market guidance of 6-8 pct adjusted diluted EPS growth for continuing group on a constant currency basis.  Full Article

UK's CMA says not refer Mckesson unit, AAH Pharma-UDG deal for phase 2 probe
Wednesday, 29 Jun 2016 

Competition and Markets Authority(CMA):UK's CMA says decided not to refer merger by Mckesson Corp unit AAH Pharmaceuticals of MASTA and Sangers to a Phase 2 investigation..  Full Article

UK's CMA says investigating UK aspects of McKesson-UDG deal
Thursday, 12 May 2016 

UK'S Competition and Markets Authority(CMA): UK'S CMA says investigating UK aspects of acquisition by McKesson Corp unit AAH Pharmaceuticals of 2 units within UDG Healthcare, Masta and Sangers (Bengaluru Newsroom: +91 80 6749 1136).  Full Article

Ex-divs to take 0.4 points off FTSE 100 on Jan. 11

LONDON, Jan 8 The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, the effect of the resulting adjustment to prices by market-makers would take 0.40 points off the index. COMPANY (RIC) DIVIDEND STOCK OPTION IMPACT (pence)

No consensus analysis data available.